CDRH, Industry to Discuss Collaboration on HHE and Recalls
So many questions swirl around recalls. When should a health hazard evaluation (HHE) be initiated? Is FDA’s HHE process different from industry’s approach? How should one estimate risk? Who are the key players in the process? What are the best practices for communication, especially on an external level?
CDRH officials, including Ron Brown, director of the recall branch at the Office of Compliance, and industry stakeholders will answer these questions at the upcoming MedTech Intelligence HHE and Recalls Conference (View the agenda), May 10–11, 2016 in Washington, DC.
What’s new this year:
- FDA update on recall and field action trends and observations
- eSubmitter and 806 reports
- New initiatives pertaining to recalls: Benefit-risk, program alignment, Case for Quality
- Draft guidance on Emerging Signals and Early Recall Notifications
- Presentation on internal FDA HHE procedures
- Detailed FDA-industry discussion and analysis of representative HHE case studies
- Ongoing evaluation and effectiveness checks of recalls
- Managing expanding recalls (a.k.a. Recall Do-overs)
This event will be followed by a one-day Global Recalls conference on May 12. More than half of all medical device recalls involve two countries or more. Streamlining the recall process while minimizing costs and mitigating adverse repercussions requires advanced knowledge, thought and planning. The conference will feature an overview of the regulatory landscape, FDA’s perspective on international recalls, HHE and risk acceptability, and global recall strategies and immediate actions.
Related Articles
-
Industry needs to understand that they do not classify a recall, the agency classifies it, advises former FDA official Steven Niedelman.
-
As of June 1, 2022, the Center for Devices and Radiological Health plans to accept all non-COVID in vitro diagnostic (IVD) pre-submissions.
-
The Experiential Learning Program (ELP) provides CDRH review staff with an opportunity to visit sites and gain a better understanding of the products they review. The 2023 ELP Site Visit Proposal period is open now until September 6, 2022.
-
Cybersecurity, remanufacturing of devices and chemical analysis for biocompatibility assessment of medical devices are among the topics FDA plans to address through draft and final guidances in 2023.
About The Author
MedTech Intelligence Staff
The MedTech Intelligence staff consists of freelance journalists and industry contributing writers with decades of experience in covering medical device issues under the categories of business, market trends, product development, quality, regulatory, and operations.
You can contact our writing staff via our Contact Page.